WilmerHale Advises Wellington Management in MBX Biosciences’ $115M Series B Financing

WilmerHale Advises Wellington Management in MBX Biosciences’ $115M Series B Financing

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Helping clients launch their businesses and transform their innovative ideas into successful companies.
On November 14, MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing round led by Wellington Management, which was represented by WilmerHale. Additional funding was provided by RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed.

The WilmerHale team representing Wellington Management consisted of Jason Kropp, Avery Reaves, Ashton Kennedy, Colleen Superko and Meghan Walsh. 
 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel